Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer

Bone Marrow Transplantation volume 34, pages 637–643 (2004)Cite this article

Summary:

The purpose of this prospective trial was to study a combined-modality treatment including local consolidation by surgery or radiotherapy and high-dose chemotherapy (HDC) followed by peripheral-blood stem-cell (PBSC) transplantation. In all, 48 patients with oligometastatic breast cancer amenable to local treatment after induction chemotherapy with epirubicin and cyclophosphamide or paclitaxel and cisplatin, depending on prior adjuvant chemotherapy, were enrolled. The median follow-up was 41 months (range, 7–85 months). PBSC were collected in 47 patients, and 40 received one or two courses of HDC. Local therapy was given in 37 patients. No treatment-related deaths occurred. Of 47 evaluable patients, 36 (75% of intention-to-treat population) had no evidence of disease or complete remission after completion of therapy. Six patients (12.5%) had partial response, two patients (4%) no change, and three patients (6%) progressive disease. The median time to progression and overall survival was 17.5 (95% confidence interval (CI), 14–21 months) and 42.2 months (95% CI, 33–52 months), respectively, and 27% of patients were progression free after 5 years. In conclusion, patients with oligometastatic breast cancer can be treated safely with this combined modality protocol with promising relapse-free survivals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Feldman AL, Welch JP . Long-term outcome in women less than 30 years of age with breast cancer. J Surg Oncol 1998; 68: 193–198.

    Article  CAS  Google Scholar 

  2. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205.

    Article  CAS  Google Scholar 

  3. Peters WP, Dansey RD, Klein JL et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000; 5: 1–13.

    Article  CAS  Google Scholar 

  4. Antman KH . Randomized trials of high-dose chemotherapy for breast cancer. Biochim Biophys Acta 2001; 1471: 89–98.

    Google Scholar 

  5. Schulman KA, Stadtmauer EA, Reed SD et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2003; 31: 205–210.

    Article  CAS  Google Scholar 

  6. Nieto Y . The verdict is not yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 2003; 88: 201–211.

    CAS  PubMed  Google Scholar 

  7. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368–1376.

    Article  CAS  Google Scholar 

  8. Dunphy FR, Spitzer G, Buzdar AU et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–1216.

    Article  CAS  Google Scholar 

  9. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–1143.

    Article  CAS  Google Scholar 

  10. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384–1391.

    Article  CAS  Google Scholar 

  11. Stadtmauer EA, O'Neill AO, Lori MS et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069–1076.

    Article  CAS  Google Scholar 

  12. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the autologous blood and marrow transplant registry. J Clin Oncol 2002; 20: 743–750.

    Article  CAS  Google Scholar 

  13. Hortobagyi GN . Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620–623.

    Article  Google Scholar 

  14. Bojko P, Stellberg W, Kuedde C et al. Kinetic study of CD34+ cells during peripheral blood stem cell collections. J Clin Apheresis 1999; 14: 18–25.

    Article  CAS  Google Scholar 

  15. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357–3365.

    Article  Google Scholar 

  16. Hortobagyi GN . Treatment of breast cancer. N Engl J Med 1998; 339: 974–984.

    Article  CAS  Google Scholar 

  17. Kamby S, Sengelov L . Pattern of dissemination and survival following isolated loco-regional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat 1997; 45: 181–192.

    Article  CAS  Google Scholar 

  18. Bathe OF, Kaklamanos IG, Moffat FL et al. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol 1999; 8: 35–42.

    Article  CAS  Google Scholar 

  19. Pocard M, Pouillart P, Asselain B et al. Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol 2000; 26: 155–159.

    Article  CAS  Google Scholar 

  20. Elias D, Maisonnette F, Druet-Cabanac M et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 2003; 185: 158–164.

    Article  Google Scholar 

  21. Wilke H, Klaassen U, Achterrath W et al. Phase I/II study with a weekly 24-h infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 1996; 7: 55–58.

    Article  CAS  Google Scholar 

  22. Nieto Y, Martin M, Alonso JL et al. Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. Breast Cancer Res Treat 1998; 50: 167–174.

    Article  CAS  Google Scholar 

  23. Nieto Y, Nawaz S, Jones RB et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002; 20: 707–718.

    Article  CAS  Google Scholar 

  24. Bojko P, Akca A, Seeber S . Outcome of 67 patients with solid tumors relapsed after high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31: 995–1000.

    Article  CAS  Google Scholar 

  25. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouacil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663–669.

    Article  CAS  Google Scholar 

  26. Rivera E, Holmes FA, Buzdar AU et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 2002; 8: 2–9.

    Article  CAS  Google Scholar 

  27. Smith TJ, Davidson NE, Schapira DV et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999; 17: 1080–1082.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, Germany

    P Bojko, A Welt, R Schleucher, D Borquez, M E Scheulen, U Vanhoefer, H Wilke, S Seeber & A Harstrick

  2. Department of Radiotherapy, West German Cancer Center, University of Essen Medical School, Essen, Germany

    C Poettgen & M Stuschke

  3. Department of Surgery, West German Cancer Center, University of Essen Medical School, Essen, Germany

    C E Broelsch

  4. Department of Thoracic Surgery, University of Essen Medical School, Ruhrlandklinik, Essen, Germany

    G Stamatis

Authors
  1. P Bojko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Welt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Schleucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Borquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M E Scheulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U Vanhoefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Poettgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Stuschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C E Broelsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Stamatis
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Harstrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Welt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bojko, P., Welt, A., Schleucher, R. et al. High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplant 34, 637–643 (2004). https://doi.org/10.1038/sj.bmt.1704613

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704613

Keywords

This article is cited by

Search

Advanced search

Quick links